We are international
• treatment options TEXT SIZE   
bone disease    back

Bisphosphonate Therapy

11.21.11   Understanding Bisphosphonate Therapy
Approximately 80% of all patients with myeloma develop bone disease. Bone disease can cause the bones to become thinner and weaker (osteoporosis), and it can make holes appear in the bone (lytic lesions). In addition to bone disease, myeloma patients may develop a condition called hypercalcemia. Both myeloma bone disease and hypercalcemia can be treated with a group of drugs called bisphosphonates.

11.21.11   IMWG Guidelines for the Use of Bisphosphonates in Myeloma

11.21.11   International Myeloma Workshop 2011
Dr. Gimsing - Bisphosphonates: Can the Dose be Lowered?
Peter Gimsing, MD
Rigshospitalet, Copenhagen University
Copenhagen, Denmark
May 3-6, 2011
Paris, France

11.21.11   Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement

06.21.11   Aredia/Zometa and osteonecrosis of the jaws

04.04.11   Salvatore L. Ruggiero, DMD, MD Talks About Osteonecrosis of the Jaw (ONJ)

11.21.11   Osteonecrosis of the Jaw and Bisphosphonates

04.18.04   Bisphosphonates For Myeloma - Current Approach To Treatment
An overview by IMF Scientific Advisor Phil Greipp

04.18.04   Bone Metabolism, Bone Disease, and the Bisphosphonates
An excellent overview by IMF Scientific Advisor Greg Mundy and Babatunde O. Oyajobi, MB, ChB, PhD

03.26.05   HealthTalk Bone Disease Webcast
IMFer Mike Katz and Dr. Paul Richardson discuss myeloma bone disease